Literature DB >> 23373626

Moyamoya syndrome associated with neurofibromatosis Type 1: perioperative and long-term outcome after surgical revascularization.

McKenzie Koss1, R Michael Scott, Mira B Irons, Edward R Smith, Nicole J Ullrich.   

Abstract

OBJECT: Children with neurofibromatosis Type 1 (NF1) can present with progressive arteriopathy of the branches of the internal carotid artery consistent with moyamoya syndrome. Clinical symptoms, radiographic evidence of ischemia, and the potential for disease progression may necessitate surgical revascularization to minimize the risk of stroke and progressive neurological deficits. This study aims to evaluate the presentation and surgical outcomes of these patients by reviewing clinical, radiographic, and angiographic data.
METHODS: A retrospective review was conducted of clinical and radiographic records of all children with NF1 who were diagnosed with moyamoya syndrome and underwent surgical revascularization between January 1988 and April 2012 at Boston Children's Hospital.
RESULTS: During this period, 39 patients (27 female and 12 male, ages 0.2-19.3 years) had both NF1 and moyamoya syndrome, of whom 32 underwent surgical revascularization with pial synangiosis. Of the 32 patients treated by surgical revascularization, 21 (66%) manifested ischemic symptoms and 18 (56%) had radiographic evidence of prior stroke at the time of moyamoya diagnosis. In total, 25 of 32 patients developed neurological symptoms prior to surgical intervention. Only 1 patient presented with hemorrhage. The average age at first surgery was 8.1 years (range 0.5-15.6 years). Perioperative complications in the first 7 days included stroke (n = 2), transient ischemic attack (n = 1), and infection (n = 1). Twenty-two patients had more than 6 months of follow-up, with an average clinical and radiographic postoperative follow-up period of 80.2 months (range 9.4-257.1 months). Of those patients with long-term follow-up, 21 (95%) of 22 demonstrated stable or improved neurological status despite radiographic evidence of moyamoya progression in 48% of patients.
CONCLUSIONS: Children with NF1-associated moyamoya syndrome are often diagnosed prior to development of fixed neurological deficits as a consequence of imaging studies obtained for other manifestations of NF1. The clinical, radiographic, and angiographic features in this population are comparable to primary moyamoya disease, with the exception of patients treated with cranial irradiation, who may be at greater risk for both stroke as well as perioperative complications. Despite radiographic evidence of progressive stenosis in 48% of patients, nearly all demonstrated stable or improved neurological status after surgical revascularization. Surgical revascularization for children with NF1 appears safe and is protective against further ischemic and neurological damage, with a 27-fold reduction in stroke rate.

Entities:  

Mesh:

Year:  2013        PMID: 23373626     DOI: 10.3171/2012.12.PEDS12281

Source DB:  PubMed          Journal:  J Neurosurg Pediatr        ISSN: 1933-0707            Impact factor:   2.375


  15 in total

1.  Salivary Cortisol Profiles of Children with Hearing Loss.

Authors:  Fred H Bess; Samantha J Gustafson; Blythe A Corbett; E Warren Lambert; Stephen M Camarata; Benjamin W Y Hornsby
Journal:  Ear Hear       Date:  2016 May-Jun       Impact factor: 3.570

2.  When and why is surgical revascularization indicated for the treatment of moyamoya syndrome in patients with RASopathies? A systematic review of the literature and a single institute experience.

Authors:  Marcello Scala; Pietro Fiaschi; Valeria Capra; Maria Luisa Garrè; Domenico Tortora; Marcello Ravegnani; Marco Pavanello
Journal:  Childs Nerv Syst       Date:  2018-05-24       Impact factor: 1.475

3.  Simultaneous Moyamoya disease and cervical spinal cord low-grade astrocytoma in a child with neurofibromatosis type 1.

Authors:  Jeffrey J Gold; Chris E Dory; Michael L Levy; John Ross Crawford
Journal:  BMJ Case Rep       Date:  2013-05-08

Review 4.  Surgical Treatment of Adult Moyamoya Disease.

Authors:  Si Un Lee; Chang Wan Oh; O-Ki Kwon; Jae Seung Bang; Seung Pil Ban; Hyoung Soo Byoun; Tackeun Kim
Journal:  Curr Treat Options Neurol       Date:  2018-05-28       Impact factor: 3.598

Review 5.  Neurovascular manifestations of connective-tissue diseases: A review.

Authors:  Sarasa T Kim; Waleed Brinjikji; Giuseppe Lanzino; David F Kallmes
Journal:  Interv Neuroradiol       Date:  2016-08-10       Impact factor: 1.610

Review 6.  Moyamoya Biomarkers.

Authors:  Edward R Smith
Journal:  J Korean Neurosurg Soc       Date:  2015-06-30

Review 7.  Moyamoya Syndrome: A Window of Moyamoya Disease.

Authors:  Ji Hoon Phi; Kyu-Chang Wang; Ji Yeoun Lee; Seung-Ki Kim
Journal:  J Korean Neurosurg Soc       Date:  2015-06-30

8.  Moyamoya syndrome and neurofibromatosis type 1.

Authors:  Euthymia Vargiami; Evdoxia Sapountzi; Dimitris Samakovitis; Spyros Batzios; Maria Kyriazi; Athanasia Anastasiou; Dimitrios I Zafeiriou
Journal:  Ital J Pediatr       Date:  2014-06-21       Impact factor: 2.638

Review 9.  A Review of the Genetics of Intracranial Berry Aneurysms and Implications for Genetic Counseling.

Authors:  Emma Hitchcock; William T Gibson
Journal:  J Genet Couns       Date:  2016-10-14       Impact factor: 2.537

Review 10.  A new horizon of moyamoya disease and associated health risks explored through RNF213.

Authors:  Akio Koizumi; Hatasu Kobayashi; Toshiaki Hitomi; Kouji H Harada; Toshiyuki Habu; Shohab Youssefian
Journal:  Environ Health Prev Med       Date:  2015-12-10       Impact factor: 3.674

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.